Immunotherapy combo offers new hope for Hard-to-Treat cancers
NCT ID NCT02961101
First seen Jan 28, 2026 · Last updated Apr 24, 2026 · Updated 10 times
Summary
This study is for people with certain cancers (like lymphoma, breast, lung, or liver cancer) that have returned or not improved with standard treatment. Researchers are testing an immunotherapy drug (anti-PD-1 antibody) alone or combined with a low-dose chemotherapy-like drug (decitabine) to see if it is safe and effective. About 250 participants aged 12 to 75 will take part, and the main goal is to track side effects and tumor response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANCIES MULTIPLE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Biotherapeutic Department of Chinese PLA General Hospital
RECRUITINGBeijing, Beijing Municipality, 100853, China
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.